Trials have shown weight loss of 15 percent to 20 percent, with around 40 percent of US adults classified as obese, based on data from the Centers for Disease Control and Prevention
With the use of GLP-1 agonists broadening to include non-diabetic overweight patients seeking weight reductiona group that now represents a large portion of our patient cohortit's crucial to recognize the different clinical considerations this population presents
Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Victoza Adverse Reactions The most common adverse reactions (incidence 5%) in clinical trials are nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation Immunogenicity-related events, including urticaria, were more common among Victoza -treated patients (0.8%) than among comparator-treated patients (0.4%) in clinical trials Drug Interactions Victoza delays gastric emptying and may impact the absorption of concomitantly administered oral medications
Many users report improved skin tone, energy, and clarity within 48 weeks
Features Flipbooks Transform any piece of content into a page-turning experience